Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Proteins with expanded polyglutamine repeats cause Huntington's disease and other neurodegenerative diseases. Transcriptional dysregulation and loss of function of transcriptional co-activator proteins have been implicated in the pathogenesis of these diseases. Huntington's disease is caused by expansion of a repeated sequence of the amino acid glutamine in the abnormal protein huntingtin (Htt). Here we show that the polyglutamine-containing domain of Htt, Htt exon 1 protein (Httex1p), directly binds the acetyltransferase domains of two distinct proteins: CREB-binding protein (CBP) and p300/CBP-associated factor (P/CAF). In cell-free assays, Httex1p also inhibits the acetyltransferase activity of at least three enzymes: p300, P/CAF and CBP. Expression of Httex1p in cultured cells reduces the level of the acetylated histones H3 and H4, and this reduction can be reversed by administering inhibitors of histone deacetylase (HDAC). In vivo, HDAC inhibitors arrest ongoing progressive neuronal degeneration induced by polyglutamine repeat expansion, and they reduce lethality in two Drosophila models of polyglutamine disease. These findings raise the possibility that therapy with HDAC inhibitors may slow or prevent the progressive neurodegeneration seen in Huntington's disease and other polyglutamine-repeat diseases, even after the onset of symptoms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The progression of neurodegeneration is slowed by treatment with deacetylase inhibitors, further emphasizing the impor- tance of a controlled balance of protein acetylation and deacetylation in cellular functions in diverse tissues (73).”
From Inhibition of CBP-Mediated Protein Acetylation by the Ets Family Oncoprotein PU.1 (2002) · cites this paper as [73]
In the citing paper
“A recent report showed that neurodegeneration triggered by expression of the polyglutamine-containing protein Httex1p involves inhibition of CBP/p300- and PCAF-AT activities (73).”
From Inhibition of CBP-Mediated Protein Acetylation by the Ets Family Oncoprotein PU.1 (2002) · cites this paper as [73]
Citations
Cites
Targeted gene expression as a means of altering cell fates and generating dominant phenotypes
Brand, A. H., & Perrimon, N. (1993) · Development · doi:10.1242/dev.118.2.401 · Cited by 9,612
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
CBP/p300 in cell growth, transformation, and development
Goodman, R. H., & Smolik, S. (2000) · Genes & Development · doi:10.1101/gad.14.13.1553 · Cited by 1,778
Saudou, F., Finkbeiner, S., Devys, D., & Greenberg, M. E. (1998) · Cell · doi:10.1016/s0092-8674(00)81782-1 · Cited by 1,595 · cited 1×
“We found that even normal repeat Htt can bind to and inhibit acetyltransferase activity ( Figs 1 and 2 ), so why is pathology associated with only expanded repeat Htt? Mutant Htt can be proteolytically processed; the pathogenic fragment localizes to the nucleus, where it is capable of inhibiting acetyltransferase acti…”
BackgroundA p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A
Yang, X.-J., Ogryzko, V. V., Nishikawa, J.-I., Howard, B. H., & Nakatani, Y. (1996) · Nature · doi:10.1038/382319a0 · Cited by 1,479 · cited 1×
“, pGST–P/CAF-AT domain (encoding amino acids 87–768), and pcDNA3 containing the cDNA for P/CA”
MethodGlutamine Repeats and Neurodegeneration
Zoghbi, H. Y., & Orr, H. T. (2000) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.23.1.217 · Cited by 1,309 · cited 1×
“The aetiology of several other neurodegenerative diseases, including spinocerebellar ataxia I and Kennedy's disease, also involves expansion of a polyglutamine repea”
BackgroundHistone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
Nucifora, F. C., Sasaki, M., Peters, M. F., Huang, H., Cooper, J. K., Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V. L., et al. (2001) · Science · doi:10.1126/science.1056784 · Cited by 1,094
Steffan, J. S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.-Z., Gohler, H., Wanker, E. E., Bates, G. P., Housman, D. E., & Thompson, L. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100110097 · Cited by 1,062 · cited 1×
“We previously found that a fragment of mutant Htt interacts directly with CBP, which contains an acetyltransferase domain and is a co-activator of numerous promoter”
BackgroundSelf-citationLuo, L., Liao, Y. J., Jan, L. Y., & Jan, Y. N. (1994) · Genes & Development · doi:10.1101/gad.8.15.1787 · Cited by 983
Cited by
Items 101–200 of 1,000
Minamiyama, M. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh131 · Cited by 260
“The histone acetyltransferase (HAT) activity of CBP is inhibited inafly model ofHD andrestored by histone deacetylase (HDAC) inhibitors, resulting in less neurodegeneration ( 24 ,25).”
BackgroundGenetic modifiers of tauopathy in Drosophila
Shulman, J. M., & Feany, M. B. (2003) · Genetics · doi:10.1093/genetics/165.3.1233 · Cited by 275
Autophagy regulates the processing of amino terminal huntingtin fragments
Qin, Z.-H. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg346 · Cited by 254
“The plasmids were stably transfected into PC12 cell lines as described in Steffan et al. ( 64 ) and Peters et al. (65), to generate PC12 cell lines that express the htt gene under the regulation of an ecdysone-sensitive insect promoter.”
MethodDrosophila Models of Neurodegenerative Diseases
Lu, B., & Vogel, H. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.3.121806.151529 · Cited by 248
“In two Drosophila models of polyQ disease, HDAC inhibitors reduced cellular toxicity associated with polyQ repeat expansion and arrested neuronal degeneration (146).”
BackgroundZhang, X., Smith, D. L., Meriin, A. B., Engemann, S., Russel, D. E., Roark, M., Washington, S. L., Maxwell, M. M., Marsh, J. L., Thompson, L. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408936102 · Cited by 246
Self-citationAtaxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes
Helmlinger, D. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh139 · Cited by 242
Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression
Yang, X.-J., & Seto, E. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(03)00015-7 · Cited by 241
The Energetics of Huntington's Disease
Browne, S. E., & Beal, M. F. (2004) · Neurochemical Research · doi:10.1023/b:nere.0000014824.04728.dd · Cited by 240
“The mutant HD gene has now been expressed in a number of different organisms, including Caenorhabditis elegans, drosophila, mice, and rats (28,37,70,71).”
BackgroundHannan, A. J. (2014) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12102 · Cited by 240
Histone deacetylase inhibitors reduce polyglutamine toxicity
McCampbell, A., Taye, A. A., Whitty, L., Penney, E., Steffan, J. S., & Fischbeck, K. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261400698 · Cited by 239
Self-citationBarrett, R. M., & Wood, M. A. (2008) · Learning & Memory · doi:10.1101/lm.917508 · Cited by 238
Drosophila melanogaster in the Study of Human Neurodegeneration
Hirth, F. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791556104 · Cited by 235
“This is particularly evident for histone deacetylase (HDAC) inhibitors, which protect against polyQ toxicity [237, 238].”
BackgroundMaher, P., Dargusch, R., Bodai, L., Gerard, P. E., Purcell, J. M., & Marsh, J. L. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddq460 · Cited by 237
Self-citationWardlaw, J. M. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.039982 · Cited by 233
“Based upon these mechanistic models, various potential drugs have been proposed. In fact, efficacy of such proposals has been demonstrated in simple cellular or more complex animal models, such as transgenic flies or mice.”
BackgroundPathogenesis of polyglutamine disorders: aggregation revisited
Michalik, A., & Van Broeckhoven, C. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg295 · Cited by 232
Okumura, K., Mendoza, M., Bachoo, R. M., DePinho, R. A., Cavenee, W. K., & Furnari, F. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605391200 · Cited by 224
Huntington’s disease: from huntingtin function and dysfunction to therapeutic strategies
Borrell-Pagès, M., Zala, D., Humbert, S., & Saudou, F. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6242-0 · Cited by 222
Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses
Sipione, S., Rigamonti, D., Valenza, M., Zuccato, C., Conti, L., Pritchard, J., Kooperberg, C., Olson, J. M., & Cattaneo, E. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddu539 · Cited by 223
Khoshnan, A., Ko, J., Watkin, E. E., Paige, L. A., Reinhart, P. H., & Patterson, P. H. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2675-04.2004 · Cited by 222
“Htt binding blocks CBPmediated gene expression, and histone deacetylase inhibitors reduce polyglutamine-induced cell death in Drosophila (Steffan et al., 2001).”
BackgroundMethodExperimental therapeutics in transgenic mouse models of Huntington's disease
Beal, M. F., & Ferrante, R. J. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1386 · Cited by 222
Singaraja, R. R. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.23.2815 · Cited by 222
Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity
Sakahira, H., Breuer, P., Hayer-Hartl, M. K., & Hartl, F. U. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182426899 · Cited by 220
Differentiation of NUT Midline Carcinoma by Epigenomic Reprogramming
Schwartz, B. E., Hofer, M. D., Lemieux, M. E., Bauer, D. E., Cameron, M. J., West, N. H., Agoston, E. S., Reynoird, N., Khochbin, S., Ince, T. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3513 · Cited by 217
“Moreover, the sequestration and inactivation of transcriptional cofactors in these complexes is reversible by HDAC inhibitors (36, 37).”
Histone deacetylase inhibitors as therapeutics for polyglutamine disorders
Butler, R., & Bates, G. P. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1989 · Cited by 214
Song, C., Kanthasamy, A., Anantharam, V., Sun, F., & Kanthasamy, A. G. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.062174 · Cited by 213
Ataxin-3 Is a Histone-binding Protein with Two Independent Transcriptional Corepressor Activities
Li, F., Macfarlan, T., Pittman, R. N., & Chakravarti, D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205259200 · Cited by 213
Li, J. Y., Popovic, N., & Brundin, P. (2005) · NeuroRX · doi:10.1602/neurorx.2.3.447 · Cited by 211
“Inhibitors of histone deacetylase (HDAC) can reverse the reduction in acetylated histones in a Drosophila model of HD and thereby reduce cell death.(88) HDAC inhibitors have also been tested in trials in R6/2 mice.”
BackgroundDrosophila in the Study of Neurodegenerative Disease
Marsh, J. L., & Thompson, L. M. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.025 · Cited by 212
“…disease (HD) (Cha, 2000), and subsequent studies have suggested that global transcriptional regulators such as acetyltransferases might be bound and affected by mutant Htt and other expanded polyglutamine-containing proteins (Hughes et al., 2001; McCampbell et al., 2001; Steffan et al., 2001).”
InfluentialSelf-citationLuthi-Carter, R. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.17.1927 · Cited by 211
Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models
Sadri-Vakili, G., Bouzou, B., Benn, C. L., Kim, M.-O., Chawla, P., Overland, R. P., Glajch, K. E., Xia, E., Qiu, Z., Hersch, S. M., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm078 · Cited by 208
Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients
Adachi, H. (2005) · Brain · doi:10.1093/brain/awh381 · Cited by 211
“Our present results strongly suggested that diffuse nuclear accumulation of mutant AR is of critical pathogenetic importance for motor symptoms as in the SBMA transgenic mouse model, although cytoplasmic accumulation may also contribute to the pathophysiology of SBMA.”
BackgroundGriñán-Ferré, C., Bellver-Sanchis, A., Izquierdo, V., Corpas, R., Roig-Soriano, J., Chillón, M., Andres-Lacueva, C., Somogyvári, M., Sőti, C., Sanfeliu, C., et al. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101271 · Cited by 208
“Furthermore, paternal diet influences gene expression (Strakovsky et al., 2011) and 5-mC in the liver of the offspring (Cooney et al., 2002) as well as chronic high-fat diet (HFD) in fathers, led to glucose intolerance in female offspring and epigenetic changes in pancreatic cells (Ng et al., 2010).”
BackgroundHistone acetyltransferases and deacetylases in the control of cell proliferation and differentiation
(2002) · Advances in Cancer Research · doi:10.1016/s0065-230x(02)86002-x · Cited by 205
“have shown that mutant Htt interacts directly with the HAT domains of CBP and PCAF and represses the HAT activities of CBP, p300, and PCAF in vitro (Steffan et al., 2001).”
BackgroundThe Activity of Antiepileptic Drugs as Histone Deacetylase Inhibitors
Eyal, S., Yagen, B., Sobol, E., Altschuler, Y., Shmuel, M., & Bialer, M. (2004) · Epilepsia · doi:10.1111/j.0013-9580.2004.00104.x · Cited by 205
“HDACs inhibitors also are able to protect cultured neurons from neuronal damage induced by oxidative stress (15) and offer in vivo protection in Drosophila (16) and transgenic mice (17) models of polyglutamine disease.”
BackgroundSchulte, J., & Littleton, J. T. (2011) · PubMed · Cited by 314
Chai, Y., Shao, J., Miller, V. M., Williams, A., & Paulson, H. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152101299 · Cited by 202
St. Laurent, R., O’Brien, L. M., & Ahmad, S. T. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.037 · Cited by 199
“We also show that genetically reducing HDAC activity, by using Sin3Alof flies, results in improvement in rotenone-induced early mortality and locomotor impairment (Steffan et al., 2001; Kontopoulos et al., 2006).”
BackgroundInfluentialFujikake, N., Nagai, Y., Popiel, H. A., Okamoto, Y., Yamaguchi, M., & Toda, T. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710521200 · Cited by 199
An Overview of the Nrf2/ARE Pathway and Its Role in Neurodegenerative Diseases
Zgorzynska, E., Dziedzic, B., & Walczewska, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179592 · Cited by 198
“The insufficiency of the antioxidant mechanism, in part, may result from the inhibition of Nrf2 activity by mtHtt, which directly interacts with the CBP/p300 dimer and inhibits its acetylase activity [155,156], and is essential for Nrf2 stability and cellular localization [157].”
BackgroundInteraction between Mutant Ataxin-1 and PQBP-1 Affects Transcription and Cell Death
Okazawa, H., Rich, T., Chang, A., Lin, X., Waragai, M., Kajikawa, M., Enokido, Y., Komuro, A., Kato, S., Shibata, M., et al. (2002) · Neuron · doi:10.1016/s0896-6273(02)00697-9 · Cited by 198
Ataxin-2 and its Drosophila homolog, ATX2, physically assemble with polyribosomes
Satterfield, T. F., & Pallanck, L. J. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl173 · Cited by 198
Ferrante, R. J., Ryu, H., Kubilus, J. K., D'Mello, S., Sugars, K. L., Lee, J., Lu, P., Smith, K., Browne, S., Beal, M. F., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2599-04.2004 · Cited by 197
“Part of this dysfunction comes from htt acting as a hyperactive glutamine - containing corepressor , inter - acting with transcriptional activators and coactivators , including Sp1 , TAFII130 , and CBP ( Steffan et al .”
BackgroundThe molecular genetics of Huntington disease — a history
Bates, G. P. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1686 · Cited by 193
Intracellular Trafficking of Histone Deacetylase 4 Regulates Neuronal Cell Death
Bolger, T. A., & Yao, T.-P. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1826-05.2005 · Cited by 191
“However, it is of great interest to note that HDAC inhibitors have been shown previously to reduce neurodegeneration caused by expanded polyglutamine proteins in Drosophila and mouse models (Steffan et al., 2001; Ferrante et al., 2003; Hockly et al., 2003; Minamiyama et al., 2004).”
BackgroundNeef, D. W., Turski, M. L., & Thiele, D. J. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000291 · Cited by 190
“HSF1A Ameliorates PolyQ-Induced Cytotoxicity in a Fly Model of Protein Conformational Disease The fruit fly Drosophila melanogaster has been used as an elegant metazoan model of human neurodegenerative diseases that include Huntington, Machado-Joseph disease (MJD) and Parkinson disease [6,50,51].”
MethodGene therapy for neurodegenerative disorders: advances, insights and prospects
Chen, W., Hu, Y., & Ju, D. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.015 · Cited by 187
Epigenetic Mechanisms in Learned Fear: Implications for PTSD
Zovkic, I. B., & Sweatt, J. D. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.79 · Cited by 187
Trinucleotide repeats and neurodegenerative disease
Everett, C. M. (2004) · Brain · doi:10.1093/brain/awh278 · Cited by 187
“Notably, in an in vivo Drosophila neurodegeneration model, inhibition of histone deacetylases (HDACs) arrests the degenerative process (Steffan et al., 2001).”
Jiang, H. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg002 · Cited by 186
“The relevance of this CBP activity for neuronal cell survival is suggested by the observed inhibition of polyQ protein-dependent toxicity when histone acetylation is restored upon inhibition of histone deacetylases ( 51 ).”
The Contribution of Nuclear Compartmentalization to Gene Regulation
Carmo-Fonseca, M. (2002) · Cell · doi:10.1016/s0092-8674(02)00650-5 · Cited by 185
Giampà, C., Laurenti, D., Anzilotti, S., Bernardi, G., Menniti, F. S., & Fusco, F. R. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013417 · Cited by 184
“Inhibition of CREB-mediated transcription has been hypothesized to contribute to neuronal loss in HD [15,16,17,18] and a decreased transcription of CREB-regulated genes is observed in HD transgenic animals [16,19,20].”
BackgroundAxonal Degeneration during Aging and Its Functional Role in Neurodegenerative Disorders
Salvadores, N., Sanhueza, M., Manque, P., & Court, F. A. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00451 · Cited by 182
“PolyQ expansions in this gene have been linked to DNA remodeling and histone modifications (Steffan et al., 2001; Sadri-Vakili et al., 2007), changes in DNA methylation and transcription of key neuronal-specific genes (Ng et al., 2013; Wood, 2013), and alteration of ncRNAs (Johnson et al., 2008;…”
BackgroundTong, J. J. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.5.1114 · Cited by 181
“Remarkably, these inhibitors have recently been found to reduce polyglutamine-dependent neurodegeneration ( 78 ), raising the hope that they can be used as a therapy for Huntington’s disease and other polyglutamine diseases.”
BackgroundThe emerging role of acetylation in the regulation of autophagy
Bánréti, Á., Sass, M., & Graba, Y. (2013) · Autophagy · doi:10.4161/auto.23908 · Cited by 164
“PML bodies contain the EP300-CREBBP acetyltransferase, which associates with the polyglutamine-containing domain of HTT.(12,13,108,109) It was further shown that CREBBP overexpression or HDAC1 knockdown modulates the acetylation state of HTT at Lys444, promotes the incorporation of mutant HTT proteins into autophagoso…”
BackgroundTargeting H3K4 trimethylation in Huntington disease
Vashishtha, M., Ng, C. W., Yildirim, F., Gipson, T. A., Kratter, I. H., Bodai, L., Song, W., Lau, A., Labadorf, A., Vogel-Ciernia, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311323110 · Cited by 177
Self-citationZhai, W., Jeong, H., Cui, L., Krainc, D., & Tjian, R. (2005) · Cell · doi:10.1016/j.cell.2005.10.030 · Cited by 178
Chatterjee, S., Sang, T.-K., Lawless, G. M., & Jackson, G. R. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddn326 · Cited by 178
Self-citationDying for a cause: invertebrate genetics takes on human neurodegeneration
Driscoll, M., & Gerstbrein, B. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1018 · Cited by 177
Wang, L., Lv, Z., Hu, Z., Sheng, J., Hui, B., Sun, J., & Ma, L. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.193 · Cited by 172
Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease
Quintanilla, R. A., & Johnson, G. V. W. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.07.010 · Cited by 173
Valor, L., Viosca, J., Lopez-Atalaya, J., & Barco, A. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990382 · Cited by 172
“A third mechanism by which mHtt can interfere with CBP function is the direct inhibition of its KAT activity [124, 125].”
BackgroundKazantsev, A., Walker, H. A., Slepko, N., Bear, J. E., Preisinger, E., Steffan, J. S., Zhu, Y.-Z., Gertler, F. B., Housman, D. E., Marsh, J. L., et al. (2002) · Nature Genetics · doi:10.1038/ng864 · Cited by 172
Self-citationApostol, B. L., Kazantsev, A., Raffioni, S., Illes, K., Pallos, J., Bodai, L., Slepko, N., Bear, J. E., Gertler, F. B., Hersch, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2628045100 · Cited by 173
Self-citationPhosphorylation of Threonine 3
Aiken, C. T., Steffan, J. S., Guerrero, C. M., Khashwji, H., Lukacsovich, T., Simmons, D., Purcell, J. M., Menhaji, K., Zhu, Y.-Z., Green, K., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.013193 · Cited by 171
Self-citationRomero, E., Cha, G.-H., Verstreken, P., Ly, C. V., Hughes, R. E., Bellen, H. J., & Botas, J. (2008) · Neuron · doi:10.1016/j.neuron.2007.11.025 · Cited by 170
Jia, H., Pallos, J., Jacques, V., Lau, A., Tang, B., Cooper, A., Syed, A., Purcell, J., Chen, Y., Sharma, S., et al. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.01.016 · Cited by 169
“Neurodegeneration Rescue in HD flies Drosophila melanogaster flies expressing N-terminal Htt fragments (N-ter Htt) (i.e. human Htt exon1 (Httex1)) were treated with HDAC inhibitors as described previously (Steffan et al., 2001).”
BackgroundMethodInfluentialSelf-citationNeurodegenerative processes in Huntington's disease
Bano, D., Zanetti, F., Mende, Y., & Nicotera, P. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.112 · Cited by 169
“Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.”
BackgroundInfluentialCurcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo
Lee, S. J., Krauthauser, C., Maduskuie, V., Fawcett, P. T., Olson, J. M., & Rajasekaran, S. A. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-144 · Cited by 166
“For example, HDAC inhibition blocks neuronal loss in a mouse model of Huntington’s disease and in Drosophila, suggesting that HDAC inhibitors are neuro-protective [23-25].”
BackgroundEhrlich, M. E. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0112-2 · Cited by 166
“These include the adenosine 3′,5′-cyclic monophosphate (cAMP) response element-binding protein (CREB)-binding protein, Specificity protein 1, TATA binding box protein, Bcl11b, repressor element-1 transcription factor/neuron restrictive silencer factor, and widely expressed components of the basal polymerase II transcr…”
BackgroundMethodInfluentialJovicic, A., Zaldivar Jolissaint, J. F., Moser, R., Silva Santos, M. D. F., & Luthi-Carter, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054222 · Cited by 164
“Histone hypoacetylation has also been observed in HD and histone deacetylase inhibitors can ameliorate disease phenotype in animal models of HD [26–28].”
BackgroundHistone deacetylase inhibitors: possible implications for neurodegenerative disorders
Hahnen, E., Hauke, J., Tränkle, C., Eyüpoglu, I. Y., Wirth, B., & Blümcke, I. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.2.169 · Cited by 165
“In vitro studies gave the first evidence that HDAC inhibitors (SB, TSA, vorinostat) are able to counteract H3/H4 hypoacetylation induced by mutant htt [37] .”
BackgroundInfluentialModelling neurodegenerative diseases in Drosophila: a fruitful approach?
Muqit, M. M. K., & Feany, M. B. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn751 · Cited by 165
Zhang, S., Xu, L., Lee, J., & Xu, T. (2002) · Cell · doi:10.1016/s0092-8674(01)00630-4 · Cited by 165
“…can arrest poly-Q- Cuticle Preparation Overnight collections of embryos were aged for 24 hr at 25 C. Thedependent neurodegeneration in fly (Steffan et al., 2001). cuticle preparation and analysis were performed as describedTogether, these data suggest that deregulation of…”
MethodSelective Neuronal Degeneration in Huntington's Disease
(2006) · Current Topics in Developmental Biology · doi:10.1016/s0070-2153(06)75002-5 · Cited by 163
Epigenetic dysregulation in cognitive disorders
Gräff, J., & Mansuy, I. M. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06787.x · Cited by 163
“One mechanism demonstrated in cell culture involves the binding of polyglutamine extension to the acetyltransferase domain of the HATs, CBP and p300 ⁄ CBP-associated factor, which reduces HAT activity and the level of acetylated H3 and H4 (Steffan et al., 2001).”
BackgroundMielcarek, M., Benn, C. L., Franklin, S. A., Smith, D. L., Woodman, B., Marks, P. A., & Bates, G. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027746 · Cited by 163
“Therefore, much effort has been directed towards developing HDAC inhibitors as an HD therapeutic [17] and initial genetic studies performed in flies and worms have confirmed that these may have a significant potential [14,18,19].”
BackgroundH UMAN N EURODEGENERATIVE D ISEASE M ODELING U SING D ROSOPHILA
Bonini, N. M., & Fortini, M. E. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.041002.131425 · Cited by 163
Inhibition of Class II Histone Deacetylases in the Spinal Cord Attenuates Inflammatory Hyperalgesia
Bai, G., Wei, D., Zou, S., Ren, K., & Dubner, R. (2010) · Molecular Pain · doi:10.1186/1744-8069-6-51 · Cited by 161
“One of these modifications is the acetylation of the ε-amino group of conserved lysine residues [14,15] that regulate transcription and facilitate neuronal plasticity, thus involving several neurological events [10,13,16-19].”
BackgroundIdentification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila
Agrawal, N., Pallos, J., Slepko, N., Apostol, B. L., Bodai, L., Chang, L.-W., Chiang, A.-S., Thompson, L. M., & Marsh, J. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500055102 · Cited by 162
Self-citationGenetic modulation of polyglutamine toxicity by protein conjugation pathways in Drosophila
Chan, H. Y. E. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.23.2895 · Cited by 161
“In a recently described fly model of Huntington’s disease, progressive degeneration of photoreceptor neurons, as revealed by the optical neutralization technique, was arrested upon administration of HDAC inhibitors ( 55 ).”
BackgroundMaurice, T., Duclot, F., Meunier, J., Naert, G., Givalois, L., Meffre, J., Célérier, A., Jacquet, C., Copois, V., Mechti, N., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301551 · Cited by 161
“…et al, 2002), seizures (Tsankova et al, 2004), learning and memory (Korzus et al, 2004; Levenson et al, 2004; Levenson and Sweatt, 2005), responses to stress and depression (Tsankova et al, 2006), drug addiction (Kumar et al, 2005) and neurodegeneration (Steffan et al, 2001; Hoshino et al, 2003).”
Zhang, S., Binari, R., Zhou, R., & Perrimon, N. (2010) · Genetics · doi:10.1534/genetics.109.112516 · Cited by 160
Elucidation of ataxin-3 and ataxin-7 function by integrative bioinformatics
Scheel, H. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg297 · Cited by 159
“Furthermore, inhibitors of histone deacetylation have been found to reduce poly(Q) mediated toxicity in a Drosophila model system ( 30 ).”
BackgroundSoliman, M. L., & Rosenberger, T. A. (2011) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-0751-3 · Cited by 161
“Similarly, HDAC inhibitors decrease polyglutamine toxicity in a mouse motor neuron‐neuroblastoma fusion cell line [29] and in Drosophila models of polyglutamine diseases [ 30 ].”
Huntington disease arises from a combinatory toxicity of polyglutamine and copper binding
Xiao, G., Fan, Q., Wang, X., & Zhou, B. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308535110 · Cited by 162
Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease
Milnerwood, A. J., Cummings, D. M., Dallérac, G. M., Brown, J. Y., Vatsavayai, S. C., Hirst, M. C., Rezaie, P., & Murphy, K. P. S. J. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl092 · Cited by 155
Ahmad Ganai, S., Ramadoss, M., & Mahadevan, V. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666151021111609 · Cited by 152
“HDAC inhibitors sodium butyrate, Trichostatin-A and SAHA were shown to arrest the neuronal degeneration caused by the poly glutamine expansion in Drosophila HD models and to also improve the survival [92].”
The role of REST in transcriptional and epigenetic dysregulation in Huntington's disease
Buckley, N. J., Johnson, R., Zuccato, C., Bithell, A., & Cattaneo, E. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.02.003 · Cited by 153
Identification of Potential Therapeutic Drugs for Huntington's Disease using Caenorhabditis elegans
Voisine, C., Varma, H., Walker, N., Bates, E. A., Stockwell, B. R., & Hart, A. C. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000504 · Cited by 154
“melanogaster [37]”
Nitric oxide neurotoxicity in neurodegenerative diseases
Kathleen, M. K. B. (2004) · Frontiers in bioscience · doi:10.2741/1268 · Cited by 167
Breda, C., Sathyasaikumar, K. V., Sograte Idrissi, S., Notarangelo, F. M., Estranero, J. G., Moore, G. G. L., Green, E. W., Kyriacou, C. P., Schwarcz, R., & Giorgini, F. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604453113 · Cited by 149
“HTT93Q exon 1 flies (27) were a gift from Larry Marsh and Leslie Thompson, Fig.”
BackgroundTherapeutics development for triplet repeat expansion diseases
Prospero, N. A. D., & Fischbeck, K. H. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1690 · Cited by 170
Histone H4 deacetylation plays a critical role in early gene silencing during neuronal apoptosis
Pelzel, H. R., Schlamp, C. L., & Nickells, R. W. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-62 · Cited by 152
“Although our experiments show that deacetylation of histones may be a central mechanism of transcriptional silencing, consistent with other reports [37,38], they do not exclude involvement of other chromatin modifications such as the methylation and demethylation of histones.”
BackgroundInfluentialA rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor
Pollitt, S. K., Pallos, J., Shao, J., Desai, U. A., Ma, A. A. K., Thompson, L. M., Marsh, J. L., & Diamond, M. I. (2003) · Neuron · doi:10.1016/s0896-6273(03)00697-4 · Cited by 151
Self-citationHuntington's disease: molecular basis of neurodegeneration
Rubinsztein, D. C., & Carmichael, J. (2003) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399403006549 · Cited by 151
Smith, M. R., Syed, A., Lukacsovich, T., Purcell, J., Barbaro, B. A., Worthge, S. A., Wei, S. R., Pollio, G., Magnoni, L., Scali, C., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu010 · Cited by 151
Self-citationPolyglutamine Diseases: Where does Toxicity Come from? What is Toxicity? Where are We Going?
Takahashi, T., Katada, S., & Onodera, O. (2010) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjq005 · Cited by 151
“HDAC inhibitors, such as sodium butyrate and suberoylanilide hydroxamic acid, which are intensively studied in therapy for cancer, ameliorate the phenotype and prolong survival in an HD model Drosophila and HD transgenic mice (Steffan et al., 2001; Ferrante et al., 2003; Hockly et al., 2003).”
BackgroundWhat have we learned from gene expression profiles in Huntington's disease?
Seredenina, T., & Luthi-Carter, R. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.07.001 · Cited by 149
Faust, K., Gehrke, S., Yang, Y., Yang, L., Beal, M. F., & Lu, B. (2009) · BMC Neuroscience · doi:10.1186/1471-2202-10-109 · Cited by 149
“Earlier studies in Drosophila Huntington's disease models showed that feeding of histone deacetylase inhibitors (either alone or in combination with congo red and cysteine) arrested progressive neuronal degeneration [98,99].”
BackgroundGiralt, A., Puigdellivol, M., Carreton, O., Paoletti, P., Valero, J., Parra-Damas, A., Saura, C. A., Alberch, J., & Gines, S. (2012) · Human Molecular Genetics · doi:10.1093/hmg/ddr552 · Cited by 149
Metadata
- Authors
- Steffan, J. S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B. L., Kazantsev, A., Schmidt, E., Zhu, Y.-Z., Greenwald, M., Kurokawa, R., Housman, D. E., Jackson, G. R., Marsh, J. L., & Thompson, L. M.
- Affiliations
- University of California, Irvine (US)
- National Institutes of Health (US)
- Massachusetts Institute of Technology (US)
- University of California San Diego (US)
- University of California, Los Angeles (US)
- Corresponding author
- Thompson, Leslie M.
- ORCID
- Venue
- Nature
- Published
- 2001-10
- Volume
- 413
- Issue
- 6857
- Pages
- 739-743
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1643390591
- Cited by
- 1,228
- References
- 28
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 26 · 2023: 21 · 2022: 31 · 2021: 35 · 2020: 35 · 2019: 30 · 2018: 37 · 2017: 34 · 2016: 40 · 2015: 46 · 2014: 63 · 2013: 65 · 2012: 55
- FWCI
- 26.66
- Type
- journal article
- Language
- en
- Open access
- green
- escholarship.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- Hereditary Disease Foundation
- National Institutes of Health
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Keywords
- histone deacetylase inhibitors, polyglutamine expansion, Huntington's disease, neurodegeneration, huntingtin exon 1, CREB-binding protein, P300, PCAF, histone acetylation, histone deacetylase, Drosophila model, transcriptional dysregulation
- MeSH terms
- Huntingtin Protein, Acetylation, Acetyltransferases, Animals, Disease Models, Animal, Drosophila, Enzyme Inhibitors, Gene Expression Regulation, Glutamine, Glutathione Transferase, Histone Deacetylases, Histones, Huntington Disease, Nerve Degeneration, Nerve Tissue Proteins, Nuclear Proteins, Peptides, Repressor Proteins, Trans-Activators, PC12 Cells, Protein Structure, Tertiary, Neurodegenerative Diseases, Repetitive Sequences, Amino Acid, Saccharomyces cerevisiae Proteins, Drosophila Proteins, Animals, Genetically Modified, E1A-Associated p300 Protein, CREB-Binding Protein, Rats, Histone Acetyltransferases, Sin3 Histone Deacetylase and Corepressor Complex, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.